Cogent Biosciences Inc. (NASDAQ: COGT) achieved a critical regulatory milestone today. The U.S. Food and Drug Administration (FDA) officially accepted the company’s New Drug Application (NDA) for bezuclastinib. Cogent developed this targeted therapy to treat patients suffering from non-advanced systemic mastocytosis.
Consequently, the FDA assigned a target action date of December 30, 2026, under the Prescription Drug User Fee Act. The agency currently anticipates a straightforward review process. Officials indicated they do not plan to convene an advisory committee meeting and have not identified any potential review issues at this stage.
Clinical Trial Foundations
The company built this regulatory submission on robust data from its pivotal SUMMIT trial. During this comprehensive study, bezuclastinib demonstrated significant improvements across all primary and secondary endpoints in patients managing this rare blood disorder. Furthermore, the 48-week dataset highlighted continued symptomatic improvement over time, validating the drug’s sustained efficacy.
Expanding the Oncology Pipeline
Beyond non-advanced systemic mastocytosis, Cogent actively advances bezuclastinib across multiple clinical indications. The biotechnology firm expects to finalize a separate drug application for gastrointestinal stromal tumor patients by April 2026. This specific application targets patients who previously received imatinib treatment.
Cogent initiated this submission under the FDA’s Real-Time Oncology Review program, capitalizing on the drug’s existing Breakthrough Therapy Designation. Additionally, the company plans to submit another application addressing patients with advanced systemic mastocytosis during the first half of 2026.
Mechanism of Action and Corporate Focus
Biologically, bezuclastinib directly inhibits the KIT D816V mutation alongside other specific mutations found in KIT exon 17. The KIT D816V mutation acts as the primary driver of systemic mastocytosis, a debilitating disease characterized by the uncontrolled proliferation of mast cells.
Operating out of dual headquarters in Waltham, Massachusetts, and Boulder, Colorado, Cogent maintains a sharp operational focus. We continue to see the firm dedicate its resources to developing precision therapies that target complex, genetically defined diseases.
For more investors relations information on Cogent Biosciences Inc. please visit www.investors.cogentbio.com.
The post Cogent Biosciences Secures FDA Acceptance for Rare Blood Disorder Treatment Application appeared first on PRISM MarketView.